

New Quality Measures to Assess Individual Doctors

BY JANE ANDERSON
Contributing Writer

The National Committee for Quality Assurance is finalizing new performance measures that will look at quality of care all the way down to the physician group and even the individual physician level.

The measures, which will form the foundation of a new Health Employer Data and Information Set (HEDIS), could require physicians to begin reporting some quality data to health plans directly—echoing other performance measurement efforts that already are underway nationwide.

The draft ambulatory care quality measures were released for public comment in October. Final measures are expected before the end of the year, said an NCQA spokesman.

“This is a big change,” said Dr. Bruce Bagley, medical director for quality improvement at the American Academy of Family Physicians (AAFP) and a member of the NCQA committee that approved the draft measures.

“Physicians now will begin to report some data from their clinical records, such

as ‘Why I didn’t give an indicated medication.’”

HEDIS, which measures quality of care, is the main tool that health plans use to track and report on their performance to payers.

Until now, HEDIS has used administrative claims data “almost exclusively” to measure quality at the health plan level, said Dr. Bagley.

Now, “NCQA has rewritten these specifications so that it’s possible to drive the

measures down to the physician level. The measures can be used at the plan level or at the physician group level or even at the individual physician level, if there are enough patients.”

The draft measures are designed to allow health plans to report on physician performance for their networks.

They include six prevention measures, such as breast cancer screening and influenza vaccination rates, as well as measures that address care for those with

coronary artery disease, depression, and asthma. Measures that address the overuse and misuse of health care services also are part of the proposed HEDIS addition.

The measures include detailed technical specifications and implementation methods, such as appropriate sample sizing, for use by health plans.

The draft measures are not new, Dr. Bagley pointed out. They were included in the National Quality Forum–endorsed

INDEX OF ADVERTISERS

Adams Respiratory Therapeutics

Delsym	20
Humibid	50

Boiron

Oscillococinum	45
----------------	----

Discovery Health Channel

CME	51
-----	----

Duramed Pharmaceuticals, Inc. (a subsidiary of Barr Pharmaceuticals)

Seasonique	15-18
------------	-------

Forest Laboratories, Inc.

Namenda	37-40
Lexapro	48a-48b

Eli Lilly and Company

Cymbalta	23-24
----------	-------

Merck & Co., Inc.

Gardasil	18a-18d
ProQuad	42a-42f
Januvia	52a-52b

Novartis Pharmaceuticals Corporation

Galvus	8a-8b
Diovan HCT	59-60

Novo Nordisk Inc.

Levemir	25-26
NovoLog Mix 70/30	41-42

Nutramax Laboratories, Inc.

CosaminDS	46
-----------	----

Ortho-McNeil Neurologics, Inc.

Topamax	6-8
---------	-----

Pfizer Inc.

Viagra	3
Detrol	10-12
Lyrica	21
Caduet	30-33

Roche Laboratories Inc.

Tamiflu	26a-26b
---------	---------

Sanofi Aventis U.S. LLC

Corporate	28-29
Sleep Leaders	47-48

Sanofi Pasteur Inc.

Fluzone	34a-34b
---------	---------

Sepracor Inc.

Lunesta	12a-12b
---------	---------

Takeda Pharmaceuticals North America, Inc.

Rozerem	54-56
---------	-------

Wyeth Pharmaceuticals Inc.

Effxor XR	4a-4d, 56a-56d
-----------	----------------

FIRST
IN A NOVEL
CLASS OF
SLEEP
AGENTS

Rozerem is indicated for the treatment of insomnia characterized by difficulty with sleep onset. Rozerem can be prescribed for long-term use. Rozerem should not be used in patients with hypersensitivity to any components of the formulation, severe hepatic impairment, or in combination with fluvoxamine. Failure of insomnia to remit after a reasonable period of time should be medically evaluated, as this may be the result of an unrecognized underlying medical disorder. Hypnotics should be administered with caution to patients exhibiting signs and symptoms of depression. Rozerem has not been studied in patients with severe sleep apnea, severe COPD, or in children or adolescents. The effects in these populations are unknown. Avoid taking Rozerem with alcohol. Rozerem has been associated with decreased testosterone levels and increased prolactin levels. Health professionals should be mindful of any unexplained symptoms possibly associated with such changes in these hormone levels. Rozerem should not be taken with or immediately after a high-fat meal. Rozerem should be taken within 30 minutes before going to bed and activities confined to preparing for bed. The most common adverse events seen with Rozerem that had at least a 2% incidence difference from placebo were somnolence, dizziness, and fatigue.

Please see adjacent Brief Summary of Prescribing Information.

National Voluntary Consensus Standards for Physician-Focused Ambulatory Care, and the AQA (which was formerly known as the the Ambulatory Care Quality Alliance) adopted these measures as part of its Recommended Starter Set of Clinical Performance Measures for Ambulatory Care.

Therefore, physician organizations have had an opportunity to see them and to comment on them prior to their release as part of HEDIS, Dr. Bagley said.

"We see these [measures] as supplementing a number of national and regional physician-level measurement ef-

forts that are already underway," said NCQA spokesman Jeff Van Ness.

Because NCQA included detailed in-

'We see these [measures] as supplementing a number of national and regional physician-level measurement efforts already underway.'

structions for implementation, "this lowers the hurdle for plans to begin to move and implement these among physicians," he said.

Nonetheless, Dr. Bagley said, once

these measures are made part of HEDIS, physician groups and individual physicians will need to develop methods to collect the necessary information without resorting to retrospective chart audits.

"We're promoting prospective data collection," such as checklists that can be filled out at the time of the patient visit, Dr. Bagley said.

NCQA released the draft measures for public comment in October. Mr. Van Ness said that most of the comments NCQA has collected have come from large national health plans, although some comments have come from physi-

cians and from other stakeholders.

He declined to provide information on the content of the comments, citing privacy concerns.

Dr. Lynne Kirk, who is the president of the American College of Physicians, said that her organization's main concern about the new quality measures was that any additional paperwork and extra costs related to the measures would become a burden to physicians.

"We aren't saying, 'Don't do it,'" she said. "We're saying, 'Let's do it in a way that actually enhances patient care.' It's going to happen, and in some ways it may improve quality." ■

Start and stay with nonscheduled Rozerem— ZERO evidence of abuse or dependence

Clinical studies show no evidence
of potential abuse, dependence, or withdrawal*

- **First and only**—nonscheduled prescription insomnia medication... not a controlled substance and approved for long-term use¹
- **First and only**—prescription insomnia medication that targets the normal sleep-wake cycle¹
- **First and only**—prescription insomnia medication with no evidence of abuse potential in clinical studies¹
- **First and only**—prescription insomnia medication that does not promote sleep by CNS depression¹
- **Promote sleep with Rozerem**—patients who took Rozerem fell asleep faster than those who took placebo¹
- **One simple 8-mg dose**¹

*Rozerem is not a controlled substance. A clinical abuse liability study showed no differences indicative of abuse potential between Rozerem and placebo at doses up to 20 times the recommended dose (N=14). Three 35-day insomnia studies showed no evidence of rebound insomnia or withdrawal symptoms with Rozerem compared to placebo (N=2082).^{1,2}

Please visit www.rozerem.com

 **Rozerem**TM
ramelteon 8-mg tablets

*Proven for sleep.
Nonscheduled for added safety.*